No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current treatment relies heavily on off-label use of products approved for the treatment of relapsing forms of MS, or anti-inflammatory agents that are not approved at all for MS. This Unmet Need content provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need in CP-MS. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.
- Multiple Sclerosis - Unmet Need - Detailed, Expanded Analysis Chronic Progressive Multiple Sclerosis
Author(s): Dr. Ankuri Setia, BDS, PGDHM
Dr. Ankuri Setia is a Biopharma Insight Analyst in the CNS team at Decision Resources Group.
She comes with a work experience of 2 years as Knowledge Management Associate with practice across multiple therapy areas and indications on various functions in secondary research, competitive intelligence and product profiling, market assessment and pipeline analysis, and clinical trials assessment. She earned a Master of Healthcare Management degree from Institute of Health Management Research, a Deemed University.